INTRODUCTION {#s1}
============

Parkinson\'s disease (PD), which is one of the most common neurodegenerative disorders, is characterized by tremors, rigidity, bradykinesia, and postural instability \[[@R1]\]. It has been estimated that approximately 9.3 million individuals older than 50 years of age around the world will suffer from PD by 2030 \[[@R2]\]. Although the etiology of PD remains poorly understood, genetic variations likely play important roles in its development \[[@R3]\]. For example, mutations in the leucine-rich repeat kinase 2 (LRRK2) gene lead to autosomal dominant PD \[[@R4], [@R5]\]. Studies have demonstrated that polymorphisms of the *LRRK2* gene are related to an increased presence of PD compared with control groups \[[@R6]\].

Recently, a study from three independent centers in Taiwan and Singapore demonstrated that *LRRK2* R1628P (rs33949390) polymorphism was a genetic risk factor for PD \[[@R7]\]. Subsequent studies have further investigated the association between the R1628P polymorphism and the risk of PD but produced conflicting results \[[@R8]--[@R20]\]. However, these discrepancies may be due inadequate statistical power, different ethnic populations, and small sample sizes. To overcome these limitations and to resolve the inconsistencies among previous studies, we conducted this meta-analysis to investigate whether the *LRRK2* R1628P polymorphism is associated with susceptibility to PD.

RESULTS {#s2}
=======

Characteristics of the published studies {#s2_1}
----------------------------------------

A total of 368 papers were yielded after our initial search. After removing duplicates and screening the titles and abstracts, 345 papers were removed. Therefore, 23 papers were selected for further full text review. Four papers were not case-control studies \[[@R21]--[@R24]\]; one was a review \[[@R25]\]; four did not provide detailed genotype data \[[@R26]--[@R29]\]. Finally, we identified fourteen eligible papers \[[@R7]--[@R20]\] including nineteen studies in this meta-analysis. Selection for eligible papers included in this meta-analysis was presented in Figure [1](#F1){ref-type="fig"}. The characteristics of these included papers are summarized in Table [1](#T1){ref-type="table"}. These papers were published from 2008 to 2014. All included studies conformed to HWE. The NOS scores of all included studies ranged from 5 to 7 stars, indicating that they were studies of high methodological quality. Seven studies were carried out in China \[[@R8], [@R9], [@R14], [@R17]--[@R20]\], three in Singapore \[[@R7], [@R19]\], and six in Taiwan \[[@R7], [@R11]--[@R13], [@R19]\]; the remaining three studies were carried out in Malaysia \[[@R15]\], Thailand \[[@R10]\] and South Korea \[[@R16]\].

###### Characteristics of included studies

  Author and year   Country       Case             Control             HWE     Genotypes Methods   NOS
  ----------------- ------------- ------ ---- ---- --------- ---- ---- ------- ------------------- -----
                                  GG     GC   CC   GG        GC   CC                               
  Gopalai2014       Malaysia      659    35   1    489       18   0    0.684   PCR                 6
  Wu2013            Taiwan        539    34   0    481       22   0    0.616   PCR                 6
  Cai2013           China         482    28   0    532       18   0    0.696   PCR--RFLP           6
  Wu-Chou2013       Taiwan        689    56   2    443       18   0    0.669   TaqMan              6
  Fu2013            China         399    47   0    382       21   0    0.591   PCR                 5
  Wang2012          China         1949   63   1    1940      31   0    0.725   PCR                 7
  Zhou2012          China         200    2    0    207       5    0    0.862   PCR                 6
  Pulkes2011        Thailand      139    14   1    151       5    0    0.834   Na                  6
  Tan2010           Singapore     226    24   0    235       15   0    0.625   MALDI-TOF           6
  Tan2010           Singapore     163    28   1    173       18   1    0.484   MALDI-TOF           6
  Tan2010           Taiwan        270    23   0    281       18   0    0.592   MALDI-TOF           6
  Tan2010           China         579    48   1    500       10   0    0.823   MALDI-TOF           5
  Kim2010           South Korea   380    3    0    378       1    0    0.980   PCR                 7
  Yu2009            China         311    17   0    294       6    0    0.861   PCR-RFLP            5
  Zhang2009         China         557    40   3    448       11   0    0.795   PCR                 6
  Ross2008          Taiwan        452    31   1    330       11   0    0.762   RFLP                6
  Ross2008          Taiwan        324    21   0    302       14   0    0.687   RFLP                6
  Ross2008          Singapore     237    13   0    244       6    0    0.848   RFLP                6
  Lu2008            Taiwan        772    60   2    523       20   0    0.662   PCR                 6

HWE, Hardy--Weinberg equilibrium; NOS, Newcastle-Ottawa Scale; Na, not available

![Selection for eligible papers included in this meta-analysis](oncotarget-07-46890-g001){#F1}

![Forest plot shows odds ratio for the associations between *LRRK2* R1628P polymorphism and PD risk (C *vs* G)](oncotarget-07-46890-g002){#F2}

Meta-analysis: LRRK2 R1628P polymorphism (rs33949390) {#s2_2}
-----------------------------------------------------

A fixed effects model was conducted for allele model (C *vs*. G), dominant model (CC + CG *vs*. GG) and heterozygous model (CG *vs*. GG) without significant heterogeneity. Due to the deficiency of CC genotypes in included studies, we could not calculate the data of recessive model and homozygous model. As shown in Table [2](#T2){ref-type="table"}, R1628P polymorphism was significantly associated with PD risk (C *vs*. G: OR, 1.97; 95% CI, 1.70-2.28, *P* \< 0.00001, Figure [2](#F2){ref-type="fig"}; CC+GC *vs*. GG: OR, 1.97; 95% CI, 1.70-2.28, *P* \< 0.00001; GC *vs*. GG: OR, 1.93; 95% CI, 1.67-2.24, *P* \< 0.00001). Stratification analyses were conducted according to ethnicity, age and country (Table [2](#T2){ref-type="table"}). The results indicated that R1628P polymorphism was significantly associated with the increased risk of PD among Chinese as well as non-Chinese (C *vs*. G, Figure [3](#F3){ref-type="fig"}). Furthermore, we found that R1628P polymorphism might increase the risk of PD patients from China, Taiwan, and Singapore. In the stratified analysis by age, we also found that R1628P polymorphism was associated with PD risk. We assessed sensitivity by omitting each study once at a time in every genetic model. The pooled ORs for the effect of R1628P polymorphism on the risk for PD indicated that our data were stable and trustworthy (Figure [4](#F4){ref-type="fig"}). Both Egger\'s and Begg\'s tests were used to evaluate the publication bias of this meta-analysis. The results revealed that there was no obvious publication bias in overall analysis for R1628P polymorphism (C *vs*. G, *P*~begg~ = 0.753 and *P*~egger~ = 0.964, Figure [5](#F5){ref-type="fig"}; CC + CG *vs*. GG, *P*~begg~ = 0.649 and *P*~egger~ = 0.987; CG *vs*. GG, *P*~begg~ = 0.552 and *P*~egger~ = 0.984).

###### Meta-analysis of associations between the R1628P polymorphism and PD risk

  Comparison     Overall and Stratification analyses   Studies            OR (95% CI)        *P*-value   P for heterogeneity   I2 (%)
  -------------- ------------------------------------- ------------------ ------------------ ----------- --------------------- --------
  C vs. G        Overall                               19                 1.97(1.70,2.28)    \<0.00001   0.41                  4.0
                 Chinese                               16                 1.97(1.69,2.30)    \<0.00001   0.34                  10.0
  Non-Chinese    3                                     1.91( 1.18,3.08)   0.009              0.37        0.0                   
                 Chinese in China                      7                  2.33(1.84,2.94)    \<0.00001   0.14                  38.0
                 Chinese in Taiwan                     6                  1.75(1.38,2.22)    \<0.00001   0.64                  0.0
                 Chinese in Singapore                  3                  1.67 (1.12,2.49)   0.01        0.83                  0.0
                 EOPD                                  3                  2.00(1.05,3.83)    0.04        0.68                  0.0
                 LOPD                                  3                  2.48 (1.24,4.95)   0.01        0.09                  59.0
  CC+GC vs. GG   Overall                               19                 1.97(1.70,2.28)    \<0.00001   0.49                  0.0
                 Chinese                               16                 1.98(1.69,2.31)    \<0.00001   0.41                  4.0
  Non-Chinese    3                                     1.86( 1.14,3.03)   0.01               0.39        0.0                   
                 Chinese in China                      7                  2.33(1.84,2.94)    \<0.00001   0.16                  36.0
                 Chinese in Taiwan                     6                  1.74(1.37,2.21)    \<0.00001   0.70                  0.0
                 Chinese in Singapore                  3                  1.73 (1.15,2.62)   0.009       0.86                  0.0
                 EOPD                                  3                  2.03(1.05,3.90)    0.03        0.67                  0.0
                 LOPD                                  3                  2.45(1.26,4.74)    0.008       0.12                  54.0
  GC vs. GG      Overall                               19                 1.93(1.67,2.24)    \<0.00001   0.57                  0.0
                 Chinese                               16                 1.99(1.68,2.36)    \<0.00001   0.62                  0.0
                 Non-Chinese                           3                  1.79 (1.09,2.93)   0.02        0.43                  0.0
                 Chinese in China                      7                  2.28(1.80,2.89)    \<0.00001   0.19                  32.0
                 Chinese in Taiwan                     6                  1.71(1.34,2.17)    \<0.0001    0.77                  0.0
                 Chinese in Singapore                  3                  1.75(1.16,2.65)    0.008       0.87                  0.0
                 EOPD                                  3                  2.06(1.09,3.92)    0.03        0.67                  0.0
                 LOPD                                  3                  2.37(1.54,3.66)    \<0.0001    0.16                  46.0

EOPD, early-onset Parkinson\'s disease; LOPD, late-onset Parkinson\'s disease; OR, odds ratio; 95% CI, 95% confidence interval.
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![Begg\'s tests for publication bias between *LRRK2* R1628P polymorphism and PD risk (C *vs* G)](oncotarget-07-46890-g005){#F5}

DISCUSSION {#s3}
==========

PD is a progressive neurodegenerative disease, which is caused primarily by the loss of dopaminergic neurons in the substantia nigra compacta and the presence of intracellular inclusions known as Lewy bodies. Although the potential etiology of PD remains poorly understood, PD is thought to be caused by both genetic and environmental factors. To date, several candidate genes including *LRRK2* have been reported to be associated with the risk of PD \[[@R30]\]. Many studies have demonstrated that genetic risk factors play a crucial role in the susceptibility to PD, and recently, the role of *LRRK2* gene variants in the development of PD have sparked a great deal of interest \[[@R31]\]. The *LRRK2* gene encodes a large multidomain protein that includes an ankyrin repeat (ANK), a leucine-rich repeat (LRR), Ras of complex proteins (ROC; GTPase), C-terminal of ROC (COR), mitogen-activated kinase kinase kinase (MAPKKK), and WD40 domains \[[@R32], [@R33]\]. The R1628P polymorphism is located in the COR region. Some studies shown that the R1628P may affect the interaction between the different functional domains of LRRK2 or its interaction with other proteins, which in turn, may result in altered LRRK2 protein function \[[@R29]\].

Many studies investigated the relationship between the *LRRK2* R1628P polymorphism and the risk of PD in Asian individuals \[[@R7]--[@R20]\], but produced contradictory results. Therefore, it was necessary to conduct a meta-analysis to determine whether this polymorphism is associated with PD susceptibility in Asian populations. The findings of the present meta-analysis suggested that *LRRK2* R1628P polymorphism was associated with an increased risk of PD among Asian populations. Previous meta-analyses \[[@R26], [@R34]\] investigating the R1628P polymorphism in terms of PD susceptibility produced conflicting findings. Ross et al. \[[@R26]\] analyzed 1,376 PD cases and 962 controls and found that R1628P is not associated with a risk of PD in Asian populations, while Wu et al. \[[@R34]\] determined that this polymorphism actually increases the risk of PD in Asians, which is consistent with the present findings. The findings of the present meta-analysis and Wu et al. are likely more robust than those of Ross et al. due to the use of larger sample sizes.

The stratification analyses in this meta-analysis also indicated that the R1628P polymorphism is significantly associated with increased risks of PD among Chinese and non-Chinese individuals, which was not found by Wu et al. \[[@R34]\]. However, the associations among the SNPs in genes associated with disorders were greatly affected by the number of subjects in the study. The results of this meta-analysis of non-Chinese individuals should be interpreted with caution because only three of the analyzed studies included non-Chinese subjects (1,232 PD cases and 1,402 controls). Furthermore, two studies investigating Japanese subjects suggested that the R1628P variant is not associated with susceptibility to PD \[[@R7], [@R27]\]. Tan et al. also demonstrated that R1628P was not a genetic risk factor for Malaysian and Indian populations \[[@R28]\]. However, these three studies did not provide detailed genotype data, and thus, it is not advisable to exclude the possibility that the R1628P polymorphism is not related to the risk of PD in non-Chinese ethnicities if the present meta-analysis had included these data \[[@R7], [@R27], [@R28]\]. Therefore, it is reasonable to assume that the *LRRK2* R1628P polymorphism may be a specific risk factor of PD among Chinese individuals, which suggests the need for future larger-scale studies to validate this assumption. The stratified analysis in the present meta-analysis also indicated that the R1628P polymorphism increases the risk of PD in Chinese patients from China, Taiwan, and Singapore. In the stratified analysis that was conducted according to age, significant associations were found in both late-onset and early-onset PD cases, but this finding should be interpreted with caution due to limited sample sizes. A sensitivity analysis indicated that the present data were stable and trustworthy.

The present meta-analysis has several limitations that should be should be taken into consideration. First, this study did not investigate the association between the *LRRK2* R1628P polymorphism and PD in Caucasian populations. Second, unpublished trials may have been excluded unintentionally and could have resulted in a publication bias; however, there was no evidence of this. Third, the present findings were based on unadjusted estimates that did not consider confounding factors such as age, sex, or environmental factors, and thus, the analysis could have been more precise if individual data were available. Fourth, the results of the stratified analyses should be interpreted with caution due to limited sample sizes. Future larger-scale studies are urgently needed to confirm these results. Fifth, it is impossible to include all the languages when we performed the literature search.

In conclusion, this meta-analysis indicates that *LRRK2* R1628P polymorphism is significantly associated with an increased risk of PD in Asians, especially among Chinese subjects. Future large-scale studies are necessary to characterize the association between the *LRRK2* R1628P polymorphism and PD.

MATERIALS AND METHODS {#s4}
=====================

Literature search {#s4_1}
-----------------

We performed a comprehensive search in PubMed, Embase, SinoMed, and the China Knowledge Resource Integrated Database to identify studies through March 1, 2016 that were related with the *LRRK2* gene polymorphism and PD. The following search terms were used: "Leucine-rich repeat kinase 2," "LRRK2," "PARK8," "Parkinson\'s disease," "Parkinson disease," "PD,""SNP," and "polymorphism". Two independent investigators conducted the search. No language or other restrictions were placed on the search. We also performed a manual search of references cited in published papers to identify other initially omitted studies. Any disagreements were resolved by consensus. Criteria for the inclusion in this analysis were: (1) studies that evaluated the association between *LRRK2* R1628P polymorphism (rs33949390) and PD in Asian populations, (2) studied on human beings, (3) study provided sufficient data to calculate the Odds ratios (ORs) and 95% confidence intervals (CIs), and *P* value, and (4) case-control study. Exclusion criteria were: (1) duplication of previous publications; (2) review, editorial, or other non-original studies; (3) studies without detailed genotype data; (4) studies without controls.

Data extraction and quality assessment {#s4_2}
--------------------------------------

For all eligible studies, the extracted information including: name of first author, publication year, country of origin, and *LRRK2* R1628P genotype frequency in cases and controls. Extraction of the data was independently performed by two authors according to the inclusion criteria. All included studies were evaluated using the

Newcastle-Ottawa Scale (NOS) \[[@R35]\]. They compared results and agreed on a consensus; disagreements were resolved by discussion.

Statistical analysis {#s4_3}
--------------------

All statistical analyses were performed using the Stata 11.0 software (StataCorp, College Station, TX, USA) and RevMan 5.3 (The Nordic Cochrane Centre, Copenhagen, Denmark). Pooled ORs and 95% CIs were calculated to evaluate the strength of the association between *LRRK2* R1628P polymorphism (rs33949390) and PD. Heterogeneity was evaluated by the Q statistic (significant at *P* \< 0.1) and I^2^ statistic (where \> 50% indicates significant heterogeneity) \[[@R36]\]. A fixed-effect model was used for comparing the trials without showing heterogeneity, whereas a random effect model was selected for comparing trials showing heterogeneity. Pooled ORs were calculated for allele model, dominant model, recessive model, homozygous model, and heterozygous model. We performed sensitivity analyses by omitting each study in turn to determine the effect on the test of heterogeneity and evaluated the stability of the overall results. Hardy-Weinberg equilibrium (HWE) was assessed in the controls using Pearson\'s χ^2^ test. Potential publication bias was investigated with the use of Begger\'s and Egger\'s linear regression test \[[@R37]\]. A *P* value \< 0.05 was considered to indicate statistically significant.

**CONFLICTS OF INTEREST**

The authors declare no conflict of interest.

CI

:   confidence interval

OR

:   odds ratio

PD

:   Parkinson\'s disease

LRRK2

:   Leucine-rich repeat kinase 2

NOS

:   Newcastle-Ottawa Scale

HWE

:   Hardy-Weinberg equilibrium
